13.63

0.51% -0.07

Oculis Holding Ag (OCS)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$13.70

Aprire:

$13.7

Volume 24 ore:

201.54K

Relative Volume:

0.30

Capitalizzazione di mercato:

$823.09M

Reddito:

Utile/perdita netta:

$-117.99M

Rapporto P/E:

-6.3701

EPS:

-2.1397

Flusso di cassa netto:

$-79.92M

1 W Prestazione:

-3.47%

1M Prestazione:

+24.25%

6M Prestazione:

-40.92%

1 anno Prestazione:

-25.92%

Intervallo 1D:

$13.27

$13.79

Intervallo di 1 settimana:

$12.92

$14.35

Portata 52W:

$10.52

$34.48

Oculis Holding Ag Stock (OCS) Company Profile

Nome

Oculis Holding Ag

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

Indirizzo

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-20

Ultimi documenti SEC

OCS's Discussions on Twitter

Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OCS Oculis Holding Ag	13.63	823.09M	0	-117.99M	-79.92M	-2.1397
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-19	Iniziato	JP Morgan	Overweight
2025-08-27	Iniziato	Needham	Buy
2023-12-05	Iniziato	Chardan Capital Markets	Buy
2023-10-05	Iniziato	Stifel	Buy
2023-06-14	Iniziato	BofA Securities	Buy
2023-06-12	Iniziato	H.C. Wainwright	Buy
2023-06-08	Iniziato	Robert W. Baird	Outperform
2023-05-10	Iniziato	Pareto	Buy
2023-04-28	Iniziato	Wedbush	Outperform

Mostra tutto

Oculis Holding Ag Borsa (OCS) Ultime notizie

Jul 11, 2026

Technical Reactions to OCS Trends in Macro Strategies - Stock Traders Daily

Jul 11, 2026

Jul 08, 2026

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com

Jul 08, 2026

Jul 07, 2026

Enterprise value to revenue forward of Oculis Holding AG – SWB:CR5 - TradingView

Jul 07, 2026

Jul 06, 2026

Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings - TradingView

Jul 06, 2026

Jul 05, 2026

Oculis stock gains after FDA trial design agreement - Investing.com

Jul 05, 2026

Jul 02, 2026

Oculis to present updates on late-stage eye dis... - Pluang

Jul 02, 2026

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - The Manila Times

Jul 02, 2026

Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat - Quiver Quantitative

Jul 02, 2026

Oculis spotlights late-stage eye drugs at Piper Sandler event - Stock Titan

Jul 02, 2026

Jun 30, 2026

Trading the Move, Not the Narrative: (OCS) Edition - Stock Traders Daily

Jun 30, 2026

Jun 25, 2026

Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway - TipRanks

Jun 25, 2026

Oculis Holding AG Actuals & Estimates (NASDAQ:OCS) - TradingView

Jun 25, 2026

Oculis Holding AG Warrants (OCSAW) See Upward Momentum Amid Modest GainsSign of Strength - dars.gov.et

Jun 25, 2026

Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029 - Stock Titan

Jun 25, 2026

OCS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire

Jun 25, 2026

Jun 23, 2026

OCSOculis Holding AG Revenue Breakdown - Finviz

Jun 23, 2026